The proteasome as a therapeutic target for lung fibrosis

Leonard H T Go, Jinal K. Gangar, Manu Jain*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

When extensive, fibrosis can impair the function of an affected organ. Despite a greater understanding of the causes and processes leading to organ fibrosis, there are a limited number of treatment options with minimal data supporting their utility. Identifying compounds for clinical use that inhibit fibrosis is an active area of investigation. In recent years, evidence for the utility of targeting the ubiquitin-proteasome system (UPS) in the inhibition of fibrosis has grown. Here we review the evidence for the interaction of the UPS with processes driving organ fibrosis, including the transforming growth factor beta pathway. We will also discuss the potential utility and harm of protea some inhibition in the treatment of organ fibrosis.

Original languageEnglish (US)
Pages (from-to)161-167
Number of pages7
JournalCurrent Enzyme Inhibition
Volume9
Issue number2
DOIs
StatePublished - Aug 28 2013

Fingerprint

Proteasome Endopeptidase Complex
Ubiquitin
Fibrosis
Lung
Transforming Growth Factor beta
Therapeutics

Keywords

  • Bortezomib
  • Fibrosis
  • Proteasome
  • Transforming growth factor-beta
  • Ubiquitin

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Drug Discovery

Cite this

Go, Leonard H T ; Gangar, Jinal K. ; Jain, Manu. / The proteasome as a therapeutic target for lung fibrosis. In: Current Enzyme Inhibition. 2013 ; Vol. 9, No. 2. pp. 161-167.
@article{fcd7be111bf54d32bd6b9af9ceadbd40,
title = "The proteasome as a therapeutic target for lung fibrosis",
abstract = "When extensive, fibrosis can impair the function of an affected organ. Despite a greater understanding of the causes and processes leading to organ fibrosis, there are a limited number of treatment options with minimal data supporting their utility. Identifying compounds for clinical use that inhibit fibrosis is an active area of investigation. In recent years, evidence for the utility of targeting the ubiquitin-proteasome system (UPS) in the inhibition of fibrosis has grown. Here we review the evidence for the interaction of the UPS with processes driving organ fibrosis, including the transforming growth factor beta pathway. We will also discuss the potential utility and harm of protea some inhibition in the treatment of organ fibrosis.",
keywords = "Bortezomib, Fibrosis, Proteasome, Transforming growth factor-beta, Ubiquitin",
author = "Go, {Leonard H T} and Gangar, {Jinal K.} and Manu Jain",
year = "2013",
month = "8",
day = "28",
doi = "10.2174/1573408011309020008",
language = "English (US)",
volume = "9",
pages = "161--167",
journal = "Current Enzyme Inhibition",
issn = "1573-4080",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

The proteasome as a therapeutic target for lung fibrosis. / Go, Leonard H T; Gangar, Jinal K.; Jain, Manu.

In: Current Enzyme Inhibition, Vol. 9, No. 2, 28.08.2013, p. 161-167.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The proteasome as a therapeutic target for lung fibrosis

AU - Go, Leonard H T

AU - Gangar, Jinal K.

AU - Jain, Manu

PY - 2013/8/28

Y1 - 2013/8/28

N2 - When extensive, fibrosis can impair the function of an affected organ. Despite a greater understanding of the causes and processes leading to organ fibrosis, there are a limited number of treatment options with minimal data supporting their utility. Identifying compounds for clinical use that inhibit fibrosis is an active area of investigation. In recent years, evidence for the utility of targeting the ubiquitin-proteasome system (UPS) in the inhibition of fibrosis has grown. Here we review the evidence for the interaction of the UPS with processes driving organ fibrosis, including the transforming growth factor beta pathway. We will also discuss the potential utility and harm of protea some inhibition in the treatment of organ fibrosis.

AB - When extensive, fibrosis can impair the function of an affected organ. Despite a greater understanding of the causes and processes leading to organ fibrosis, there are a limited number of treatment options with minimal data supporting their utility. Identifying compounds for clinical use that inhibit fibrosis is an active area of investigation. In recent years, evidence for the utility of targeting the ubiquitin-proteasome system (UPS) in the inhibition of fibrosis has grown. Here we review the evidence for the interaction of the UPS with processes driving organ fibrosis, including the transforming growth factor beta pathway. We will also discuss the potential utility and harm of protea some inhibition in the treatment of organ fibrosis.

KW - Bortezomib

KW - Fibrosis

KW - Proteasome

KW - Transforming growth factor-beta

KW - Ubiquitin

UR - http://www.scopus.com/inward/record.url?scp=84882795223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882795223&partnerID=8YFLogxK

U2 - 10.2174/1573408011309020008

DO - 10.2174/1573408011309020008

M3 - Article

VL - 9

SP - 161

EP - 167

JO - Current Enzyme Inhibition

JF - Current Enzyme Inhibition

SN - 1573-4080

IS - 2

ER -